Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients

This is the first reported study on the combination of enzalutamide and abiraterone acetate. Serial bone biopsy molecular characterisation identified a candidate molecular signature of response. Phase 3 studies testing the combination across the prostate cancer spectrum will be reported.